Patent ID: 9737532
Date: 2017-08-22
CPC Classifications: A61K,A61P,C12Q,G01N

Claim:
1. A method of screening a therapeutic agent for treating an ischemia/reperfusion injury, comprising: contacting a test substance with a p53-wild-type tester cell, wherein the p53-wild-type tester cell expresses an amount of Parp1 protein when the cell is contacted with Caylin2 that is lower than the amount of Parp1 protein in the cell before contact with Caylin2, and measuring the expression of Parp1 protein in the tester cell to obtain a first measurement value; contacting the tester cell with the test substance and a proteasome inhibitor, and measuring the expression of Parp1 protein in the tester cell to obtain a second measurement value; and selecting the test substance as a candidate substance for use as a therapeutic agent for treating an ischemia/reperfusion injury when the second measurement value is greater than the first measurement value, the test substance selected as a candidate substance activating a proteasome to degrade Parp1 protein when the test substance is contacted with the p53-wild-type tester cell.